Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Disease with No Approved Treatment Initial Clinical Trial Results Expected in 2020 LEXINGTON, Mass., Jan. 29, 2019 -- (H... Biopharmaceuticals, Ophthalmology, Mergers & Acquisitions Aldeyra Therapeutics, Helio Vision, Vitreoretinopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news